medigraphic.com
ISSN 1560-4381 (Print)

2020, Number 2

<< Back Next >>

Correo Científico Médico 2020; 24 (2)

New therapeutic approaches to dyslipidemias

Ojeda AI, Expósito LA, González BSN, Freire MEN, Campoverde BJA

Language: Spanish
References: 38
Page: 720-740
PDF size: 307.23 Kb.


ABSTRACT

Dyslipidemia is a major modifiable risk factor for cardiovascular disease due to atherosclerosis. A literature review was conducted with the descriptors dyslipidemia and treatment, in English and Spanish, in PubMed, PubMed Central, SciELO and Clinical Key. Emphasis was placed on new therapeutic modalities approved or under development that act mainly on molecular targets: subtilisin/kexin type 9 paraprotein converter (PCSK9), cholesterol ester transfer protein (CETP), angiopoietin-like protein 3 (ANGPTL3), receptor activated by peroxisome alpha proliferator (PPARα), acetyl-CoA carboxylase, ATP citrate lyase, diacylglycerol acyltransferase, apo A1, apo C-III, apo (a) and microsomal triglyceride transfer protein (MTP). The key therapeutic modalities were monoclonal antibodies (alirocumab and evolocumab), no-sense oligonucleotides (inclisiran, volanesorsen), vaccines, genome editing, enzyme inhibitors (gemcaben, prodigastat) and nutritional supplements (omega 3).


REFERENCES

  1. Rygiel K. Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. Curr Cardiol Rev. 2018[citado 25/05/2019]; 14(1):67-76. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872265

  2. Diéguez Martínez M, Miguel Soca P, Rodríguez Hernández R, López Báster J, Ponce de León D, Reyna Carralero J. Prevalencia de hipertrigliceridemia y factores de riesgo cardiovascular en estudiantes de la Universidad de Ciencias Médicas. Holguín, 2014-2015. Medisur. 2018 [citado 25/01/2020 ]; 16(1): 35-46. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2018000100007&lng=es

  3. Miguel Soca PE, Rivas Estévez M, Sarmiento Teruel Y, Mariño Soler AL, Marrero Hidalgo M, Mosqueda Batista L, et al. Prevalence of Metabolic Syndrome Risk Factors in Adults in Holguín, Cuba (2004–2013). MEDICC Review. 2016 [citado 17 /03/2017]; 18(1-2). Disponible en: https://www.scielosp.org/article/medicc/2016.v18n1-2/28-33/

  4. Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019[citado 15/02/2020];1500. Disponible en: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-7827-5#citeas

  5. Rodríguez Hernández R, Alberteris Rodríguez A, López Báster J, Diéguez Martínez M, Miguel Soca PE, Cruz Abreu Y. Factores de riesgo en pacientes con lupus eritematoso sistémico y obesidad abdominal en Holguín, Cuba. CCM. 2017 [citado 28/01/ 2020]; 21( 4 ): 1152-1173. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812017000400016&lng=es

  6. Rodríguez Hernández R, Diéguez Martínez M, López Báster J, Alberteris Rodríguez A, de Valle Fernández IB, Miguel Soca PE. Comportamiento clínico epidemiológico del síndrome metabólico en pacientes con lupus eritematoso sistémico. Rev Cubana Reumatol. 2017 [citado 18 /05/2017]; 18(3). Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/503

  7. Wong McClure RA, Gregg EW, Barceló A, Lee K, Abarca Gómez L, Sanabria López L, et al. Prevalence of metabolic syndrome in Central America: a cross-sectional population-based study. Rev Panam Salud Publica. 2015[citado 14/02/2017]; 38(3):202-208. Disponible en: https://www.scielosp.org/pdf/rpsp/2015.v38n3/202-208/en

  8. Rivas Vázquez D, Miguel Soca PE, Llorente Columbié Y, Marrero Ramírez GM. Comportamiento clínico epidemiológico del síndrome metabólico en pacientes adultos. Rev Cubana Med Gen Integr. 2015[citado 18 /02/2017];31(3).Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252015000300001&lng=es

  9. Corella del Toro I, Miguel Soca PE, Aguilera Fuentes PL, Suárez Peña E. Factores de riesgo asociados al síndrome metabólico en niños y adolescentes con obesidad. Rev Cubana Pediatr. 2016[citado 22/01/2020]; 88 (1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312016000100003&lng=es

  10. Ochoa Expósito K, Rivas Estévez M, Miguel Soca PE, Batista Hernández A, Leyva Sicilia Y. Ensayo no aleatorizado: impacto de cambios en la dieta y ejercicios físicos en pacientes adultos con síndrome metabólico. CCM. 2015 [citado 24/02/2020];19(3). Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/2156

  11. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med. 2019[citado 24/02/2020]; 34(4):723-771. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610190

  12. Bonaccio M, Di Castelnuovo A, Costanzo S, Persichillo M, De Curtis A, Cerletti C, et al. Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study. Int J Cardiol. 2019 [citado 24/02/2020]; 276: 248-254. Disponible en: https://doi.org/10.1016/j.ijcard.2018.11.117

  13. Kirkpatrick CF, Bolick JP, Kris Etherton PM, Sikand G, Aspry KE, Soffer DE, et al. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol. 2019[citado 24/02/2020]; 13 (5): 689-711. Disponible en: https://www.sciencedirect.com/science/article/pii/S1933287419302673

  14. Parhofer KG. New approaches to address dislipidemia. Curr Opin Lipidol. 2017[citado 24/02/2020]; 28(6):452-457. Disponible en: https://journals.lww.com/co-lipidology/Abstract/2017/12000/New_approaches_to_address_dyslipidemia.3.aspx

  15. Escobar C, Anguita M, Arrarte V, Barrios V, Cequier Á, Cosín Sales J, et al. Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología. Rev Esp Cardiol. 2020[citado 24/02/2020]; 73 (2): 161-167. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0300893219303690

  16. Hegele RA, Tsimikas S. Lipid-Lowering Agents. Circ Res. 2019[citado 24/02/2020]; 124(3):386-404. Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.313171

  17. Kosmas CE, Sourlas A, Silverio D, Montan PD, Guzman E. Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. World J Cardiol. 2019[citado 24/02/2020]; 11(11): 256–265.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885448/pdf/WJC-11-256.pdf

  18. Wills-Sanín B, Rincón A, Montenegro AC, Buitrago-Sandoval AF. Inhibidores de la paraproteína convertasa subtilisina/kexina tipo 9: una alternativa de manejo para las dislipidemias. Rev Colomb Cardiol. 2017[citado 24/02/2020]; 24(4): 411-416. Disponible en: https://www.sciencedirect.com/science/article/pii/S0120563316302406

  19. McGowan MP, Dehkordi SHH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc. 2019[citado 24/02/2020]; 8(24). Disponible en: https://www.ahajournals.org/doi/full/10.1161/JAHA.119.013225

  20. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, et al. Reductions in Atherogenic Lipids and Major Cardiovascular Events. A Pooled Analysis of 10 ODYSSEY trials comparing Alirocumab with Control. Circulation. 2016[citado 24/02/2020]; 134(24):1931–1943. Disponible en: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.024604

  21. Vetcher D. Impacto y oportunidad de CRISPR-Cas9 en Cardiología. RACI. 2017[citado 24/02/2020]; 8(2):62-66. Disponible en: http://adm.meducatium.com.ar/contenido/articulos/11400620066_758/pdf/11400620066.pdf

  22. Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Human Molec Genetics. 2014[citado 24/02/2020]; 23(1):40–46. Disponible en: https://academic.oup.com/hmg/article/23/R1/R40/2900693

  23. Johns DG, Wang SP, Rosa R, Hubert J, Xu S, Chen Y, et al. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case. Pharmacol Res Perspect. 2019[citado 24/02/2020];7(6):00543. Disponible en: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1002/prp2.543

  24. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W. Effects of anacetrapib in patients with atherosclerotic vascular disease. J Vacul Surge. 2017[citado 24/02/2020];64(1).Disponible en: https://www.clinicalkey.es/#!/content/playContent/1-s2.0-S074152141732431X?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS074152141732431X%3Fshowall%3Dtrue&referrer=

  25. Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, William J, et al. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation. 2019[citado 24/02/2020]; 140(6): 470–486. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686956/pdf/cir-140-470.pdf

  26. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020[citado 24/02/2020]; 41(1): 99–109. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588/pdf/ehz785.pdf

  27. Yamashita S, Masuda D, Matsuzawa Y. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases. J Atheroscler Thromb. 2019[citado 24/02/2020];26(5): 389–402. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514171/

  28. Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016[citado 24/02/2020];10(5):1212-1222. Disponible en: https://www.sciencedirect.com/science/article/pii/S1933287416302756

  29. van Zwol W, Rimbert A, Kuivenhoven JA. The Future of Lipid-Lowering Therapy. J Clin Med. 2019 Jul[citado 24/02/2020]; 8(7): 1085. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678580/pdf/jcm-08-01085.pdf

  30. Reiner Ž. Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circ J. 2018[citado 24/02/2020]; 48(12):1097-1119. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221868/pdf/kcj-48-1097.pdf

  31. Vogt A. Lipoprotein (a)-antisense therapy. Clin Res Cardiol Suppl. 2019; 14(Suppl 1):51-56.

  32. Hassan M, Wagdy K. ASGR1 - a new target for lowering non-HDL cholesterol. Glob Cardiol Sci Pract. 2016[citado 24/02/2020]; 2016(2):201614. Disponible en: https://globalcardiologyscienceandpractice.com/index.php/gcsp/article/view/17

  33. Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL, et al. Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. N Engl J Med. 2016[citado 24/02/2020]; 374(22):2131-2141. Disponible en: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1508419?articleTools=true&downloadfile=showPdf&articleTools=true&doi=10.1056/NEJMoa1508419

  34. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019[citado 24/02/2020]; 14:19–30. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615460

  35. Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, et al. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. J Atheroscler Thromb. 2019[citado 24/02/2020]; 26(4): 368–377. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456458/pdf/jat-26-368.pdf

  36. Ben Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, et al. Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. Adv Ther. 2019[citado 24/02/2020]; 36(7): 1786–1811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824397/pdf/12325_2019_Article_985.pdf

  37. Kris Etherton PM, Richter CK, Bowen KJ, Skulas Ray AC, Jackson KH, Petersen KS, et al. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. Methodist Debakey Cardiovasc J. 2019[citado 24/02/2020]; 15(3): 171–178. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822654/

  38. Natto ZS, Yaghmoor W, Alshaeri HK, Van Dyke TE. Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis. Scientific Reports. 2019[citado 24/02/2020]; 9(2019): 18867. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906408/pdf/41598_2019_Article_54535.pdf




2020     |     www.medigraphic.com